• 1
    Schirmer, R. H., H. Adler, M. Pickhardt and E. Mandelkow (2011) Lest we forget you–methylene blue. Neurobiol. Aging 32, 2325. e7-16.
  • 2
    Oz, M., D. E. Lorke, M. Hasan and G. A. Petroianu (2010) Cellular and molecular actions of methylene blue in the nervous system. Med. Res. Rev. 31, 93117.
  • 3
    Floyd, R. A., J. E. Jr Schneider and D. P. Dittmer (2004) Methylene blue photoinactivation of RNA viruses. Antiviral Res. 61, 14151.
  • 4
    Schirmer, R. H., B. Coulibaly, A. Stich, M. Scheiwein, H. Merkle, J. Eubel, K. Becker, H. Becher, O. Muller, T. Zich, W. Schiek and B. Kouyate (2003) Methylene blue as an antimalarial agent. Redox Rep. 8, 2725.
  • 5
    Bradberry, S. M. (2003) Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue. Toxicol. Rev. 22, 1327.
  • 6
    Pelgrims, J., F. De Vos, J. Van den Brande, D. Schrijvers, A. Prove and J. B. Vermorken (2000) Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: Report of 12 cases and a review of the literature. Br. J. Cancer 82, 2914.
  • 7
    Oz, M., D. E. Lorke and G. A. Petroianu (2009) Methylene blue and Alzheimer's disease. Biochem. Pharmacol. 78, 92732.
  • 8
    Medina, D. X., A. Caccamo and S. Oddo (2011) Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 21, 1409.
  • 9
    Atamna, H. and R. Kumar (2010) Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. J. Alzheimer's Dis.: JAD 20(Suppl. 2), S43952.
  • 10
    Peter, C., D. Hongwan, A. Kupfer and B. H. Lauterburg (2000) Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur. J. Clin. Pharmacol. 56, 24750.
  • 11
    Weiner, L., E. Roth and I. Silman (2011) Targeted oxidation of Torpedo californica acetylcholinesterase by singlet oxygen. Photochem. Photobiol. 87, 30816.
  • 12
    Tacal, O. and I. Ozer (2006) Inhibition of choline oxidase by quinoid dyes. J. Enzyme Inhib. Med. Chem. 21, 7837.
  • 13
    Yucel, Y. Y., O. Tacal and I. Ozer (2008) Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Arch. Biochem. Biophys. 478, 2015.
  • 14
    Kucukkilinc, T. and I. Ozer (2007) Multi-site inhibition of human plasma cholinesterase by cationic phenoxazine and phenothiazine dyes. Arch. Biochem. Biophys. 461, 2948.
  • 15
    Moan, J. and Q. Peng (2003) An outline of the hundred-year history of PDT. Anticancer Res. 23, 3591600.
  • 16
    Tardivo, J. P., A. D. Giglio, C. S. de Oliveira, D. S. Gabrielli, H. C. Junqueira, D. P. Tada, D. Severino, R. F. de FatimaTurchiello and M. S. Baptista (2005) Methylene blue in photodynamic therapy: From basic mechanism to clinical applications. Photodiagnosis Photodyn. Ther. 2, 175191.
  • 17
    Papin, J. F., R. A. Floyd and D. P. Dittmer (2005) Methylene blue photoinactivation abolishes west Nile virus infectivity in vivo. Antiviral Res. 68, 847.
  • 18
    Saxena, A., W. Sun, C. Luo, T. M. Myers, I. Koplovitz, D. E. Lenz and B. P. Doctor (2006) Bioscavenger for protection from toxicity of organophosphorus compounds. J. Mol. Neurosci. 30, 1458.
  • 19
    Lockridge, O., L. M. Schopfer, G. Winger and J. H. Woods (2005) Large scale purification of butyrylcholinesterase from human plasma suitable for injection into monkeys; a potential new therapeutic for protection against cocaine and nerve agent toxicity. J. Med. CBR Def. 3, 120.
  • 20
    Masson, P. and O. Lockridge (2010) Butyrylcholinesterase for protection from organophosphorus poisons: Catalytic complexities and hysteretic behavior. Arch. Biochem. Biophys. 494, 107120.
  • 21
    Ellman, G. L., K. D. Courtney, V. Jr Andres and R. M. Featherstone (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 8895.
  • 22
    Karnovsky, M. J. and L. Roots (1964) A “direct-coloring” thiocholine method for cholinesterases. J. Histochem. Cytochem. 12, 21921.
  • 23
    Tarentino, A. L. and T. H. Jr Plummer (1994) Enzymatic deglycosylation of asparagine-linked glycans: Purification, properties, and specificity of oligosaccharide-cleaving enzymes from flavobacterium meningosepticum. Methods Enzymol. 230, 4457.
  • 24
    Lockridge, O. and B. N. La Du (1982) Loss of the interchain disulfide peptide and dissociation of the tetramer following limited proteolysis of native human serum cholinesterase. J. Biol. Chem. 257, 120128.
  • 25
    Davies, M. J. (2003) Singlet oxygen-mediated damage to proteins and its consequences. Biochem. Biophys. Res. Commun. 305, 76170.
  • 26
    Ronsein, G. E., M. C. de Oliveira, M. H. de Medeiros and P. Di Mascio (2009) Characterization of O(2) ((1)delta(g))-derived oxidation products of tryptophan: A combination of tandem mass spectrometry analyses and isotopic labeling studies. J. Am. Soc. Mass Spectrom. 20, 18897.
  • 27
    Ronsein, G. E., M. C. de Oliveira, S. Miyamoto, M. H. de Medeiros and P. Di Mascio (2008) Tryptophan oxidation by singlet molecular oxygen [O2(1Deltag)]: Mechanistic studies using 18O-labeled hydroperoxides, mass spectrometry, and light emission measurements. Chem. Res. Toxicol. 21, 127183.
  • 28
    Gracanin, M., C. L. Hawkins, D. I. Pattison and M. J. Davies (2009) Singlet-oxygen-mediated amino acid and protein oxidation: Formation of tryptophan peroxides and decomposition products. Free Radic. Biol. Med. 47, 92102.
  • 29
    Qin, J. and B. T. Chait (1997) Identification and characterization of posttranslational modifications of proteins by MALDI ion trap mass spectrometry. Anal. Chem. 69, 40029.
  • 30
    Swiderek, K. M., M. T. Davis and T. D. Lee (1998) The identification of peptide modifications derived from gel-separated proteins using electrospray triple quadrupole and ion trap analyses. Electrophoresis 19, 98997.
  • 31
    O'Hair, R. A. (2000) The role of nucleophile–electrophile interactions in the unimolecular and bimolecular gas-phase ion chemistry of peptides and related systems. J. Mass Spectrom. 35, 137781.
  • 32
    Garrison, W. M. (1987) Reaction mechanisms in the radiolysis of peptides, polypeptides and proteins. Chem. Rev. 87, 38398.
  • 33
    Hawkins, C. L. and M. J. Davies (2001) Generation and propagation of radical reactions on proteins. Biochim. Biophys. Acta 1504, 196219.
  • 34
    Triquigneaux, M., M. Ehrenshaft, L. Weiner, E. Roth, I. Silman, R. Mason and L. Detereding (2011) Specfic oxidation of Torpedo californica acetylcholinesterase by singlet oxygen: Identification of N-formyl-kynurenine tryptophan derivatives by mass spectrometry. Free Radic. Biol. Med. 51, S32.
  • 35
    Paz, A., E. Roth, Y. Ashani, Y. Xu, V. L. Shnyrov, J. L. Sussman, I. Silman and L. Weiner (2012) Structural and functional characterization of the interaction of the photosensitizing probe methylene blue with Torpedo californica acetylcholinesterase. Protein Sci. 87, 113852.
  • 36
    Lockridge, O., C. F. Bartels, T. A. Vaughan, C. K. Wong, S. E. Norton and L. L. Johnson (1987) Complete amino acid sequence of human serum cholinesterase. J. Biol. Chem. 262, 54957.
  • 37
    Nachon, F., Y. Nicolet, N. Viguie, P. Masson, J. C. Fontecilla-Camps and O. Lockridge (2002) Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase: Expression, purification, characterization and crystallization. Eur. J. Biochem. 269, 6307.
  • 38
    Nicolet, Y., O. Lockridge, P. Masson, J. C. Fontecilla-Camps and F. Nachon (2003) Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 278, 411417.
  • 39
    Kolarich, D., A. Weber, M. Pabst, J. Stadlmann, W. Teschner, H. Ehrlich, H. P. Schwarz and F. Altmann (2008) Glycoproteomic characterization of butyrylcholinesterase from human plasma. Proteomics 8, 25463.
  • 40
    Maley, F., R. B. Trimble, A. L. Tarentino and T. H. Jr Plummer (1989) Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal. Biochem. 180, 195204.
  • 41
    Robinson, N. E. and A. B. Robinson (2001) Deamidation of human proteins. Proc. Natl. Acad. Sci. U S A 98, 1240913.
  • 42
    Lenz, D. E., D. M. Maxwell, I. Koplovitz, C. R. Clark, B. R. Capacio, D. M. Cerasoli, J. M. Federko, C. Luo, A. Saxena, B. P. Doctor and C. Olson (2005) Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem. Biol. Interact. 157–158, 20510.
  • 43
    Saxena, A., W. Sun, J. M. Fedorko, I. Koplovitz and B. P. Doctor (2011) Prophylaxis with human serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman or VX. Biochem. Pharmacol. 81, 1649.
  • 44
    Saxena, A., P. Tipparaju, C. Luo and B. P. Doctor (2010) Pilot-scale production of human serum butyrylcholinesterase suitable for use as a bioscavenger against nerve agent toxicity. Process Biochem. 45, 13131318.
  • 45
    Weber, A., H. Butterweck, U. Mais-Paul, W. Teschner, L. Lei, E. M. Muchitsch, D. Kolarich, F. Altmann, H. J. Ehrlich and H. P. Schwarz (2011) Biochemical, molecular and preclinical characterization of a double-virus-reduced human butyrylcholinesterase preparation designed for clinical use. Vox Sang. 100, 28597.